5/16/2013

The FDA approved Bayer and Algeta's Xofigo injection, or radium-223 dichloride, to treat patients with castration-resistant prostate cancer, three months earlier than expected. Bayer also submitted an application in Europe and hopes to win approval in coming months.

Related Summaries